2017 Update of the Drug Resistance Mutations in HIV-1

2017 Update of the Drug Resistance Mutations in HIV-1

Online publication: 01/12/2016 Journal: Topics in Antiviral Medicine

Abstract:

The 2017 edition of the IAS–USA drug resistance mutations list updates the figures last published in November 2015. The mutations listed are those that have been identified by specific criteria for evidence and drugs described. The figures are designed to assist practitioners in identifying key mutations associated with resistance to antiretroviral drugs and, therefore, in making clinical decisions regarding antiretroviral therapy.

The 2017 edition of the IAS–USA drug resistance mutations list updates the figures last published in November 2015.1 The Q148K mutation was added to the bar for the integrase strand transfer inhibitor dolutegravir, and the bars for multinucleoside and nucleotide analogue reverse transcriptase inhibitor (nRTI) resistance were modified to indicate specifically that thymidine analogue mutations do not affect susceptibility to emtricitabine and lamivudine.

Authors: Wensing AM, Calvez V, Günthard HF, Johnson VA, Paredes R, Pillay D, Shafer RW, Richman DD

Subscribe to our newsletter

Back to Top
Irsi Caixa

Promoted by:

'La Caixa' Foundation Generalitat de Catalunya - Departament de Salut

 

HR Excellence in Research

Member of:

Cerca

In cooperation with: